AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30912213 — intervention group
Group type: COMPARATOR
Intervention: 30:70 mixed human insulin
Number of subjects: 40
Study 26730560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Text Contact (HFTC)
Number of subjects: 8000
Study 26730560 — intervention group
Group type: COMPARATOR
Intervention: Low-Frequency Text Contact (LFTC)
Number of subjects: 8000
Study 26165264 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant removal
Number of subjects: 162
Study 26165264 — intervention group
Group type: COMPARATOR
Intervention: No implant removal (Control)
Number of subjects: 162
Study 22872593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 6632
Study 22872593 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 6632
Study 21607821 — intervention group
Group type: EXPERIMENTAL
Intervention: Extralight titanized polypropylene mesh (ELW group) TiMesh(®) 16 g/m(2) without any fixation
Number of subjects: 300
Study 21607821 — intervention group
Group type: COMPARATOR
Intervention: Standard heavyweight polypropylene mesh (HW group) Prolene 90 g/m(2) fixed with two absorbable sutures
Number of subjects: 300
Study 18303984 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA)
Number of subjects: 19
Study 18303984 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 19
Study 18303984 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study 16438762 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 3 x 40 mg
Number of subjects: 93
Study 16438762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 12559678 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 60
Study 12559678 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) (25 mg)
Number of subjects: 60
Study 12559678 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 11436909 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic analgesia administered in the emergency department (ED)
Number of subjects: 0
Study 11436909 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic analgesia
Number of subjects: 0
Study 9592510 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning process-based tutorials
Number of subjects: 2
Study 9592510 — intervention group
Group type: COMPARATOR
Intervention: Theory-based tutorials
Number of subjects: 2
Study 7530026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivity to gp41 epitopes (amino acids 571-585, 736-750, and perhaps 650-663)
Number of subjects: 65
Study 7530026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivity to gp120 epitopes (amino acids 466-480 and 475-486) and one gp41 epitope (amino acids 547-576)
Number of subjects: 65
Study 7530026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies to HIVLAI
Number of subjects: 65
Study 7530026 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of 102 HIV-1 Env peptides
Number of subjects: 65
Study 7530026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of results
Number of subjects: 65
Study 2968102 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanetetraphosphonate
Number of subjects: 0
Study 2968102 — intervention group
Group type: COMPARATOR
Intervention: Albumin colloid
Number of subjects: 0
Study 31523249 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mucoadhesive films
Number of subjects: 60
Study 31523249 — intervention group
Group type: COMPARATOR
Intervention: Placebo mucoadhesive films
Number of subjects: 60
Study 28943912 — intervention group
Group type: EXPERIMENTAL
Intervention: H2H nutrition management
Number of subjects: 86
Study 28943912 — intervention group
Group type: COMPARATOR
Intervention: Routine nutrition management
Number of subjects: 86
Study 26281947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered self-help intervention
Number of subjects: 69
Study 23281973 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion when hemoglobin fell below 7 g/dL)
Number of subjects: 921
Study 23281973 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion when hemoglobin fell below 9 g/dL)
Number of subjects: 921
Study 23281973 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 921
Study 23281973 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 921
Study 20825901 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 124
Study 20825901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including furosemide, oxygen, and high-dose boluses of isosorbide dinitrate)
Number of subjects: 124
Study 20825901 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124
Study 20825901 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 124
Study 19515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once a day
Number of subjects: 464
Study 19515413 — intervention group
Group type: COMPARATOR
Intervention: Exenatide 10 microg twice a day
Number of subjects: 464
Study 17090235 — intervention group
Group type: EXPERIMENTAL
Intervention: Online teaching module
Number of subjects: 48
Study 15612859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicotine (35 mg) patch
Number of subjects: 158
Study 15612859 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 158
Study 11282204 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenC)
Number of subjects: 322
Study 9352695 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 70
Study 9352695 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 70
Study 9352695 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 70
Study 9352695 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 70
Study 9352695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TUVP and TURP
Number of subjects: 70
Study 8462384 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 16
Study 8462384 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3081923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 8
Study 3081923 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (30 mg)
Number of subjects: 8
Study 3081923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg) and Yohimbine (30 mg) together
Number of subjects: 8
Study 3081923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30027590 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked milk in the form of muffin for 6 months followed by baked cheese in the form of pizza for another 6 months
Number of subjects: 84
Study 30027590 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to strictly avoid any milk products for 1 year
Number of subjects: 84
Study 28028958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames (EG)
Number of subjects: 60
Study 28028958 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 25216572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-based autosegmentation (AS + R)
Number of subjects: 40
Study 25216572 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation (MS)
Number of subjects: 40
Study 25216572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-based autosegmentation (AS)
Number of subjects: 40
Study 25216572 — intervention group
Group type: COMPARATOR
Intervention: Attending approved OARs
Number of subjects: 40
Study 23090523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen (10 mg hydrocodone and 650 mg acetaminophen)
Number of subjects: 120
Study 23090523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23090523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen
Number of subjects: 120
Study 20406432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phenol virgin olive oil (398 ppm)
Number of subjects: 20
Study 20406432 — intervention group
Group type: COMPARATOR
Intervention: Low-phenol virgin olive oil (70 ppm)
Number of subjects: 20
Study 17669242 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum argininosuccinate lyase (ASL)
Number of subjects: 291
Study 17669242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT)
Number of subjects: 291
Study 17669242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST)
Number of subjects: 291
Study 17669242 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ASL levels in liver cancer, acute hepatitis, liver cirrhosis, chronic hepatitis
Number of subjects: 291
Study 16124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided and double-injection (ND) group
Number of subjects: 90
Study 16124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and double-injection (UD) group
Number of subjects: 90
Study 16124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and single-injection (US) group
Number of subjects: 90
Study 11936548 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective equipment during functional analysis
Number of subjects: 2
Study 10519465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored weight-loss materials
Number of subjects: 198
Study 10519465 — intervention group
Group type: COMPARATOR
Intervention: AHA brochure
Number of subjects: 198
Study 10519465 — intervention group
Group type: COMPARATOR
Intervention: AHA-content formatted to look like tailored materials
Number of subjects: 198
Study 8619007 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-2327 (3 mg)
Number of subjects: 12
Study 8619007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.8 mg)
Number of subjects: 12
Study 8619007 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-2327 (2 mg)
Number of subjects: 12
Study 2057271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 54
Study 2057271 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypnotic distraction/relaxation
Number of subjects: 54
Study 2057271 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (control)
Number of subjects: 54
Study 6611720 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercises with the perineometer exerciser
Number of subjects: 22
Study 6611720 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises without the perineometer exerciser
Number of subjects: 22
Study 31502498 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a previously-completed prospective clinical trial
Number of subjects: 95
Study 31502498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in MCS
Number of subjects: 95
Study 31502498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with preserved language function (MCS+)
Number of subjects: 95
Study 29791829 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab every 2 weeks
Number of subjects: 52
Study 29791829 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab every 4 weeks
Number of subjects: 52
Study 29791829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 27161018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase (0.6 mg/kg)
Number of subjects: 3310
Study 27161018 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase (0.9 mg/kg)
Number of subjects: 3310
Study 24624911 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and XDH
Number of subjects: 589
Study 24624911 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional validation studies by siRNA knockdown in cancer cell lines
Number of subjects: 589
Study 24624911 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1
Number of subjects: 589
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ED treatment including oral prednisone at 60 mg and inhalation of nebulized albuterol and ipratropium
Number of subjects: 28
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial eNO levels
Number of subjects: 28
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in pre‐ versus posttreatment eNO (ΔeNO)
Number of subjects: 28
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PEF
Number of subjects: 28
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔPEF
Number of subjects: 28
Study 23394510 — intervention group
Group type: EXPERIMENTAL
Intervention: ED visit duration
Number of subjects: 28
Study 20029212 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Visits (HV)
Number of subjects: 0
Study 20029212 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 0
Study 20029212 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline scenario
Number of subjects: 0
Study 20029212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (HV favored)
Number of subjects: 0
Study 20029212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (CT favored)
Number of subjects: 0
Study 18757663 — intervention group
Group type: EXPERIMENTAL
Intervention: HSIL cytology with HPV16-positive, low-grade or worse colposcopic impression, HSIL or equivocal HSIL cytology
Number of subjects: 411
Study 18757663 — intervention group
Group type: EXPERIMENTAL
Intervention: HSIL cytology with HPV16-negative, less than low-grade colposcopic impression, not called HSIL or equivocal HSIL
Number of subjects: 411
Study 18757663 — intervention group
Group type: EXPERIMENTAL
Intervention: HSIL cytology (general population)
Number of subjects: 411
Study 15973602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 70% stenosis
Number of subjects: 62
Study 15973602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 80% stenosis
Number of subjects: 62
Study 15973602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 90% stenosis
Number of subjects: 62
Study 15973602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stenoses > 95%
Number of subjects: 62
Study 15973602 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 62
Study 12748465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine injection
Number of subjects: 56
Study 10480222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein supplement (7.8 g/d)
Number of subjects: 19
Study 10480222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9124982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for wound infections
Number of subjects: 25
Study 9124982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for burn infections
Number of subjects: 25
Study 1832209 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (20 mg)
Number of subjects: 95
Study 1832209 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 95
Study 7080890 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine acidification in nonsmoking females after smoking one cigarette
Number of subjects: 0
Study 7080890 — intervention group
Group type: COMPARATOR
Intervention: Urine alkalinization in nonsmoking females after smoking one cigarette
Number of subjects: 0
Study 7080890 — intervention group
Group type: COMPARATOR
Intervention: Males (no specific intervention mentioned)
Number of subjects: 0
Study 31882030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium silicate (Biodentine)
Number of subjects: 58
Study 31882030 — intervention group
Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 58
Study 28887154 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric only (ERE)
Number of subjects: 33
Study 28887154 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentrically biased resistance exercise (EBRE)
Number of subjects: 33
Study 28887154 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance exercise (TRE)
Number of subjects: 33
Study 25891010 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41
Study 25891010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23857436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general and epidural anesthesia (group GE)
Number of subjects: 54
Study 23857436 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 54
Study 21360470 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour bicarbonate hemodialysis
Number of subjects: 11
Study 21360470 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour bicarbonate hemodialysis
Number of subjects: 11
Study 19411801 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program on blood-borne infection control
Number of subjects: 0
Study 17515172 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting theta activity in the rostral anterior cingulate cortex (ACC)
Number of subjects: 20
Study 17515172 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting theta activity in the rostral ACC
Number of subjects: 20
Study 17515172 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain voxelwise approach
Number of subjects: 20
Study 15346745 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft in an experimental putty carrier plus a calcium sulfate barrier (PUT)
Number of subjects: 24
Study 15346745 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived xenograft (BDX) plus a collagen membrane
Number of subjects: 24
Study 11842065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g/kg of [(13)C]glucose (approximately 2 g/min)
Number of subjects: 6
Study 11842065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 218
Study 9818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,800 mg/day
Number of subjects: 218
Study 9818846 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine 600 mg/day
Number of subjects: 218
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 471
Study 7981446 — intervention group
Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term OC users (4 years or longer)
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with tumors > 2 cm
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with axillary node-positive tumors (1-3 nodes)
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with axillary node-positive tumors (≥ 4 nodes)
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with low estrogen receptor content
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with low progesterone receptor content
Number of subjects: 471
Study 7981446 — intervention group
Group type: EXPERIMENTAL
Intervention: OC users with poorly differentiated tumors
Number of subjects: 471
Study 2024986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 16
Study 2024986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7032839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 0
Study 7032839 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0
Study 7032839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study 31426673 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant (RAD1901)
Number of subjects: 0
Study 31426673 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator's choice)
Number of subjects: 0
Study 27637736 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional star-shape taping for 7 days
Number of subjects: 120
Study 27637736 — intervention group
Group type: COMPARATOR
Intervention: Sham functional taping for 7 days
Number of subjects: 120
Study 27637736 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention, one session
Number of subjects: 120
Study 26495909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme distress class
Number of subjects: 232
Study 26495909 — intervention group
Group type: EXPERIMENTAL
Intervention: High depressive and anxiety symptom class
Number of subjects: 232
Study 26495909 — intervention group
Group type: COMPARATOR
Intervention: Low distress class
Number of subjects: 232
Study 26495909 — intervention group
Group type: COMPARATOR
Intervention: Moderate distress class
Number of subjects: 232
Study 26495909 — intervention group
Group type: COMPARATOR
Intervention: High NICU-related distress class
Number of subjects: 232
Study 24424076 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 52
Study 24424076 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 52
Study 22964434 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation ON
Number of subjects: 0
Study 22964434 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation OFF
Number of subjects: 0
Study 19764666 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer closure (closure of skin and subcutaneous tissues together)
Number of subjects: 160
Study 19764666 — intervention group
Group type: COMPARATOR
Intervention: Two layer closure (closure of skin and subcutaneous tissues separately)
Number of subjects: 160